Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA E453K||lung squamous cell carcinoma||no benefit||PIK3CA inhibitor||Taselisib||Case Reports/Case Series||Actionable||In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet its primary endpoint for response rate in patients with lung squamous cell carcinoma harboring PIK3CA mutations, resulting in no response in a patient harboring PIK3CA E453K (PMID: 31158500; NCT02785913).||31158500|
|PIK3CA E453K||breast cancer||resistant||PI3K Inhibitor (Pan)||Buparlisib||Preclinical - Cell culture||Actionable||In a preclinical study, breast cancer cells expressing PIK3CA E453K demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477).||29636477|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|